title: Budesonide suspension nebulization treatment in Chinese pediatric patients with cough variant asthma: a multi-center observational study.
abstract: To describe the impact of nebulized budesonide inhalation suspension (BIS) on guardian-reported symptoms in Chinese pediatric patients with cough variant asthma (CVA).
  
  
  
  This was a secondary analysis of a prospective, non-interventional study conducted at 39 Chinese sites. Patients with CVA aged ≤5 years were classified according to the severity of baseline symptoms: mild (symptom score ≤3) or severe (symptom score >3). Daytime and night-time symptom scores, disease control, use of bronchodilators, and improvements in symptoms control were compared after 1, 3, 5 and 7 weeks of treatment between groups.
  
  
  
  Among 914 patients, 821 (89.8%) completed the 7-week treatment. Among all patients, 368 (40.3%) were classified as mild CVA and 529 (57.9%), as severe CVA. Symptom scores in the severe group were higher than those in the mild group at weeks 1, 3, and 5 (p < 0.05), but not at week 7 (p > 0.05). Further, more patients in the mild group achieved disease control at any time point (98.6% at 3 weeks and 99.7% at 7 weeks), compared with the patients in the severe group (p < 0.001). The proportion of patients requiring bronchodilators differed between the groups until week 5 (p < 0.001). No severe or drug-related adverse events were reported.
  
  
  
  Individualized BIS treatment should be formulated according to the severity of baseline symptoms in CVA patients. Patients with mild CVA showed improvement after a shorter treatment time, while patients with severe CVA might require a longer time to respond to the treatment.
authors.affiliation: a Department of Pediatrics , Shanghai General Hospital, Shanghai Jiaotong University , Shanghai , P.R. China .
authors.forename: Xiaojian
authors.initials: X
authors.lastname: Zhou
authors.affiliation: b Department of Pediatrics , First Affiliated People's Hospital, Shanghai Jiaotong University , Shanghai , P.R. China .
authors.forename: Jianguo
authors.initials: J
authors.lastname: Hong
authors.affiliation: c First Affiliated Hospital, Jilin University , Changchun , Jilin , China .
authors.forename: Huanji
authors.initials: H
authors.lastname: Cheng
authors.affiliation: d Wuxi City Eighth People's Hospital , Wuxi , Jiangsu , P.R. China .
authors.forename: Juanjuan
authors.initials: J
authors.lastname: Xie
authors.affiliation: e Children's Hospital of Quanzhou City , Quanzhou , Fujian , China .
authors.forename: Jianzhi
authors.initials: J
authors.lastname: Yang
authors.affiliation: f Children's Hospital of Jiangxi Province , Jiangxi , Nanchang , China .
authors.forename: Qiang
authors.initials: Q
authors.lastname: Chen
authors.affiliation: g Guangdong People's Hospital , Guangzhou , Guangdong , China .
authors.forename: Shaoru
authors.initials: S
authors.lastname: He
authors.affiliation: h People's Hospital of Hunan Province , Changsha , Hunan , P.R. China .
authors.forename: Yun
authors.initials: Y
authors.lastname: Li
authors.affiliation: i Hubei Maternal & Child Healthcare Hospital , Wuhan , Hubei , P.R. China , and.
authors.forename: Xiaoqin
authors.initials: X
authors.lastname: Zhou
authors.affiliation: j Second Affiliated Hospital, Wenzhou Medical College , Wenzhou , Zhejiang , P.R. China.
authors.forename: Changchong
authors.initials: C
authors.lastname: Li
mesh_terms: D000280:Administration, Inhalation; D044466:Asian People; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D003371:Cough / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D013535:Suspensions
chemical_list: D001993:Bronchodilator Agents; D013535:Suspensions; D019819:Budesonide
keywords: Baseline symptoms; budesonide suspension nebulization treatment; cough variant asthma